Amgen Inc., a leading biotechnology company headquartered in the United States, has been at the forefront of innovation since its founding in 1980. With a strong presence in major operational regions including Europe and Asia, Amgen focuses on developing therapies in areas such as oncology, nephrology, and inflammation. Renowned for its pioneering biologic medicines, Amgen's core products include Enbrel, Neulasta, and Prolia, which are distinguished by their ability to target specific disease pathways effectively. The company has achieved significant milestones, including the introduction of the first recombinant human erythropoietin, Epogen, which transformed the treatment of anaemia. As a prominent player in the biotechnology industry, Amgen continues to excel, holding a strong market position and receiving numerous accolades for its commitment to scientific excellence and patient care.
How does Amgen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Amgen's score of 42 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Amgen reported total carbon emissions of approximately 1,538,000,000 kg CO2e, comprising 153,000,000 kg CO2e from Scope 1, 12,000,000 kg CO2e from Scope 2, and a significant 1,384,000,000 kg CO2e from Scope 3 emissions. The company has set ambitious targets to reduce its carbon footprint, aiming for a 55% reduction in absolute Scope 1 and 2 greenhouse gas emissions by 2027, using 2019 as the baseline year. This commitment includes achieving 100% renewable electricity sourcing across its operations by 2027, which is expected to result in a reduction of about 50% in operational carbon emissions. As of 2023, Amgen has achieved 54% of its targeted reductions for Scope 1 and 2 emissions. The company is also focused on ensuring that 73% of its suppliers, by spend, will have science-based targets by 2027. These initiatives align with the Science Based Targets initiative (SBTi) and reflect Amgen's commitment to sustainability and climate action within the pharmaceutical and biotechnology sector.
Access structured emissions data, company-specific emission factors, and source documents
2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 144,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 290,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | - | - | - | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Amgen is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.